Excellent overall and chronic graft‐ versus ‐host‐disease‐free event‐free survival in Fanconi anaemia patients undergoing matched related‐ and unrelated‐donor bone marrow transplantation using alemtuzumab–Flu–Cy: the UK experience

2021 ◽  
Author(s):  
Fanette Bernard ◽  
Chakradhara Rao S. Uppungunduri ◽  
Stephan Meyer ◽  
Michelle Cummins ◽  
Katharine Patrick ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Fanconi Anaemia ◽  
Unrelated Donor ◽  
Event Free Survival ◽  
Free Survival ◽  
Graft Versus Host ◽  
Donor Bone Marrow ◽  
The Uk ◽  
Disease Free

scholarly journals Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases [published erratum appears in Blood 1990 Aug 1;76(3):654]

Blood ◽  
1990 ◽  
Vol 75 (8) ◽  
pp. 1728-1732 ◽  
Author(s):  
PB McGlave ◽  
P Beatty ◽  
R Ash ◽  
JM Hows
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Acute Gvhd ◽  
Disease Free Survival ◽  
Myelogenous Leukemia ◽  
Unrelated Donor ◽  
Free Survival ◽  
Donor Bone Marrow ◽  
Grade Ii ◽  
Disease Free

Abstract From April, 1985, to February, 1989, 102 consecutive patients received unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia (CML) at four centers. Median age of the group was 31 years (range, 4.5 to 51 years). Fifty-four patients were in first chronic phase (CP) at time of transplantation, and 48 had evidence of more advanced disease (AD) (accelerated phase, 32; blast crisis, 9; second CP, 7). In 44 cases, the donor and recipient were identical at the HLA A, B, and DR loci and were nonreactive in bidirectional mixed leukocyte culture (MLC) (“matched”). In 58 cases, nonidentity between donor and recipient could be determined at at least one HLA locus or in bidirectional MLC (“mismatche”). Fifty-eight patients were prepared for transplantation with a combination of cyclophosphamide and fractionated total body irradiation (FTBI) and received acute graft- versus-host disease (GVHD) prophylaxis consisting of methotrexate alone or in combination with cyclosporine, prednisone, or antithymocyte globulin (ATG). In 44 cases, patients received preparative agents in addition to cyclophosphamide and FTBI, and marrow depleted of mature T lymphocytes by ex vivo incubation with either anti-CD3 antibody plus complement (n = 24) or Campath-1 (n = 20). Engraftment defined by a peripheral blood neutrophil count greater than 0.5 X 10(9)/L was demonstrated in 92 cases and occurred at a median of 22 days (range, 11 to 46 days). In 10 cases, peripheral blood evidence of engraftment did not occur, and in one case, engraftment was followed by aplasia. Hematologic relapse was seen in four cases. Recurrence or persistence of the Ph1 chromosome without evidence of hematologic relapse occurred in four additional cases. The incidence of grade II to IV acute GVHD is 65% (95% confidence interval [CI], +/- 10%). After adjustment for recipient age and donor matching status, recipients of T lymphocyte- depleted donor marrow had a significantly lower incidence of grade II to IV acute GVHD (P less than .01); however, T depletion was not significantly associated with improved survival (P = .34), disease-free survival (P = .51), or increased incidence of relapse (P = .39). Of 102 patients, 46 are alive, with a median survival of 12 months (range, 3 to 46 months), and the Kaplan-Meier estimate of disease-free survival is 29% (95% CI, +/- 9%) for the entire group at 2 1/2 years.(ABSTRACT TRUNCATED AT 400 WORDS)

scholarly journals Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases [published erratum appears in Blood 1990 Aug 1;76(3):654]

Blood ◽  
1990 ◽  
Vol 75 (8) ◽  
pp. 1728-1732 ◽  
Author(s):  
PB McGlave ◽  
P Beatty ◽  
R Ash ◽  
JM Hows
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Acute Gvhd ◽  
Disease Free Survival ◽  
Myelogenous Leukemia ◽  
Unrelated Donor ◽  
Free Survival ◽  
Donor Bone Marrow ◽  
Grade Ii ◽  
Disease Free

From April, 1985, to February, 1989, 102 consecutive patients received unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia (CML) at four centers. Median age of the group was 31 years (range, 4.5 to 51 years). Fifty-four patients were in first chronic phase (CP) at time of transplantation, and 48 had evidence of more advanced disease (AD) (accelerated phase, 32; blast crisis, 9; second CP, 7). In 44 cases, the donor and recipient were identical at the HLA A, B, and DR loci and were nonreactive in bidirectional mixed leukocyte culture (MLC) (“matched”). In 58 cases, nonidentity between donor and recipient could be determined at at least one HLA locus or in bidirectional MLC (“mismatche”). Fifty-eight patients were prepared for transplantation with a combination of cyclophosphamide and fractionated total body irradiation (FTBI) and received acute graft- versus-host disease (GVHD) prophylaxis consisting of methotrexate alone or in combination with cyclosporine, prednisone, or antithymocyte globulin (ATG). In 44 cases, patients received preparative agents in addition to cyclophosphamide and FTBI, and marrow depleted of mature T lymphocytes by ex vivo incubation with either anti-CD3 antibody plus complement (n = 24) or Campath-1 (n = 20). Engraftment defined by a peripheral blood neutrophil count greater than 0.5 X 10(9)/L was demonstrated in 92 cases and occurred at a median of 22 days (range, 11 to 46 days). In 10 cases, peripheral blood evidence of engraftment did not occur, and in one case, engraftment was followed by aplasia. Hematologic relapse was seen in four cases. Recurrence or persistence of the Ph1 chromosome without evidence of hematologic relapse occurred in four additional cases. The incidence of grade II to IV acute GVHD is 65% (95% confidence interval [CI], +/- 10%). After adjustment for recipient age and donor matching status, recipients of T lymphocyte- depleted donor marrow had a significantly lower incidence of grade II to IV acute GVHD (P less than .01); however, T depletion was not significantly associated with improved survival (P = .34), disease-free survival (P = .51), or increased incidence of relapse (P = .39). Of 102 patients, 46 are alive, with a median survival of 12 months (range, 3 to 46 months), and the Kaplan-Meier estimate of disease-free survival is 29% (95% CI, +/- 9%) for the entire group at 2 1/2 years.(ABSTRACT TRUNCATED AT 400 WORDS)

High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation

2003 ◽  
Vol 76 (12) ◽  
pp. 1758-1762 ◽  
Author(s):  
Margaret L. MacMillan ◽  
Gretchen A. Radloff ◽  
William R. Kiffmeyer ◽  
Todd E. DeFor ◽  
Daniel J. Weisdorf ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Graft Versus Host Disease ◽  
Marrow Transplantation ◽  
Interleukin 2 ◽  
Unrelated Donor ◽  
Host Disease ◽  
Graft Versus Host ◽  
Donor Bone Marrow ◽  
Acute Graft

scholarly journals Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experience

1998 ◽  
Vol 21 (5) ◽  
pp. 447-453 ◽  
Author(s):  
ChM Zwaan ◽  
MH Van Weel-Sipman ◽  
WE Fibbe ◽  
M Oudshoorn ◽  
JMJJ Vossen
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Fanconi Anaemia ◽  
Unrelated Donor ◽  
Donor Bone Marrow

scholarly journals Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to Chemotherapy

2008 ◽  
Vol 26 (26) ◽  
pp. 4326-4332 ◽  
Author(s):  
Nancy J. Bunin ◽  
Stella M. Davies ◽  
Richard Aplenc ◽  
Bruce M. Camitta ◽  
Kenneth B. DeSantes ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Unrelated Donor ◽  
Free Survival ◽  
Donor Bone Marrow ◽  
Primary Induction ◽  
Induction Failure ◽  
Acute Myeloid

PurposeIdentify prognostic factors that influence outcome after unrelated donor bone marrow transplantation in children with acute myeloid leukemia (AML).Patients and MethodsIncluded are 268 patients (age ≤ 18 years) with AML in second complete remission (n = 142), relapse (n = 90), or primary induction failure (n = 36) at transplantation. All patients received bone marrow grafts from an unrelated donor and a myeloablative conditioning regimen. Cox regression models were constructed to identify risk factors that influence outcome after transplantation.ResultsIn this analysis, the only risk factor that predicted leukemia recurrence and overall and leukemia-free survival was disease status at transplantation. The 5-year probabilities of leukemia-free survival were 45%, 20%, and 12% for patients who underwent transplantation at second complete remission, relapse, and primary induction failure, respectively. As expected, risk of acute but not chronic graft-versus-host disease (GVHD) was lower with T-cell–depleted bone marrow grafts; T-cell–depleted grafts were not associated with higher risks of leukemia recurrence. We observed similar risks of leukemia relapse in patients with and without acute and chronic GVHD.ConclusionChildren who underwent transplantation in remission had a superior outcome compared with children who underwent transplantation during relapse or persistent disease. Nevertheless, 20% of children who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effective therapy in a significant proportion of children with recurrent or primary refractory AML.

scholarly journals High-risk HLA alleles for severe acute graft- versus -host disease and mortality in unrelated donor bone marrow transplantation

Haematologica ◽  
2016 ◽  
Vol 101 (4) ◽  
pp. 491-498 ◽  
Author(s):  
Satoko Morishima ◽  
Koichi Kashiwase ◽  
Keitaro Matsuo ◽  
Fumihiro Azuma ◽  
Toshio Yabe ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
High Risk ◽  
Graft Versus Host Disease ◽  
Marrow Transplantation ◽  
Unrelated Donor ◽  
Hla Alleles ◽  
Graft Versus Host ◽  
Donor Bone Marrow ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document